Biostage wins court order requiring insurer to pay legal defense; to host investor webinar Jan 27

Harvard Apparatus Regenerative Technology, Inc.

Court ordered Medmarc to continue paying Biostage's legal defense in a wrongful death suit over a tracheal implant, finding Medmarc breached its duty and awarding attorneys' fees.
Biostage discontinued tracheal implant development and now focuses on esophageal implant, which has FDA approval for a clinical trial.
Interim CEO David Green will host webinars on Jan 27 to discuss the clinical trial, capital raising, and NASDAQ uplisting.
A second webinar is scheduled for Jan 27 at 8pm ET / Jan 28 9am Beijing time for investor Q&A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.